Understanding and Reducing Cardiovascular Disease in Type 1 Diabetes Mellitus (R01 Clinical Trial Optional)

The summary for the Understanding and Reducing Cardiovascular Disease in Type 1 Diabetes Mellitus (R01 Clinical Trial Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Understanding and Reducing Cardiovascular Disease in Type 1 Diabetes Mellitus (R01 Clinical Trial Optional): The goal of this funding opportunity is to support research that enhances the understanding of the pathophysiology and epidemiology of cardiovascular disease (CVD) among individuals with Type 1 Diabetes Mellitus (T1DM), and support the development of interventions to reduce CVD risk among these individuals. The overall goal is to develop evidence-based guidelines to prevent or reduce CVD complications of T1DM across the lifespan. This funding opportunity will support epidemiologic studies to refine risk assessment, mechanistic studies to enhance understanding of the pathophysiology of CVD in T1DM, and small clinical trials that could inform the future development of larger trials focused on preventing or reducing the CVD complications of T1DM. The focus of this FOA is on macrovascular disease that includes outcomes of myocardial infarction, stroke, peripheral artery disease, heart failure, cardiomyopathy, cardiac arrythmias and cardiac autonomic neuropathy and/or the study of coronary arteries, cerebral arteries, large peripheral arteries, cardiac tissue, atherosclerosis, thrombosis and lipoprotein metabolism. Research can include the effect of microvascular disease on the development of macrovascular disease, e.g., DKD, but the emphasis must be on CVD.

Federal Grant Title:	Understanding and Reducing Cardiovascular Disease in Type 1 Diabetes Mellitus (R01 Clinical Trial Optional)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Food and Nutrition Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-HL-21-014
Type of Funding:	Grant
CFDA Numbers:	93.837, 93.847
CFDA Descriptions:	Information not provided
Current Application Deadline:	October 15th, 2021
Original Application Deadline:	October 15th, 2021
Posted Date:	January 6th, 2021
Creation Date:	January 6th, 2021
Archive Date:	November 20th, 2021
Total Program Funding:	$6,240,000
Maximum Federal Grant Award:	$500,000
Minimum Federal Grant Award:
Expected Number of Awards:	8
Cost Sharing or Matching:	No
Last Updated:	January 6th, 2021

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-21-014.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Chronic Kidney Disease in Children Central Biochemistry Laboratory (U24 Clinical Trial Not...; • Limited Competition for Continuation of the Prospective Study of Chronic Kidney Disease in...; • Limited Competition for Continuation of the Prospective Study of Chronic Kidney Disease in...; • ARDS, Pneumonia, and Sepsis Phenotyping Consortium Clinical Centers (U01 Clinical Trial No...; • The Relationship Between Hypertension and Inflammation; • Community-Responsive Interventions to Reduce Cardiovascular Risk in American Indians and A...; • Weight Loss in Obese Adults with Cardiovascular Risk Factors: Clinical Interventions (U01)
More Grants from the National Institutes of Health: • Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Opti...; • Advancing HIV service delivery through pharmacies and pharmacists (R01 Clinical Trial Opti...; • Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Required); • Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Humans...; • Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required)